<p>CIBC 私人財富集團有限公司在最近向證券交易委員會的披露中表示，在第四季度將其在 Bio-Rad Laboratories, Inc.（紐約證券交易所代碼：BIO - 免費報告）的股份減少了 2.9%。該公司在本季度出售了 1,243 股後，持有 42,106 股該醫療研究公司的股票。根據其最近向證券交易委員會的備案，CIBC 私人財富集團有限公司持有 Bio-Rad Laboratories 的 0.15% 股份，價值 14,500,000 美元。</p>
<p>獲取 <strong>Bio-Rad Laboratories</strong> 的提醒：</p>
<ul>
<li>標普 500 震盪：新進入者推動市場動能</li>
</ul>
<p>其他大型投資者最近也對該公司的持倉進行了調整。Venturi 財富管理有限公司在第四季度將其在 Bio-Rad Laboratories 的股份增加了 2,175.0%。Venturi 財富管理有限公司現在擁有 91 股該醫療研究公司的股票，價值 30,000 美元，此前在上個季度又購買了 87 股。Picton Mahoney 資產管理在第四季度將其在 Bio-Rad Laboratories 的股份增加了 55.6%。Picton Mahoney 資產管理現在擁有 98 股該醫療研究公司的股票，價值 32,000 美元，此前在上個季度又收購了 35 股。Asset Planning Inc 在第四季度收購了 Bio-Rad Laboratories 的新股份，價值約 33,000 美元。UMB 銀行在第四季度將其在 Bio-Rad Laboratories 的持股增加了 41.6%。UMB 銀行現在擁有 109 股該醫療研究公司的股票，價值 36,000 美元，此前在上個季度又購買了 32 股。最後，Cape Investment Advisory Inc 在第四季度購買了 Bio-Rad Laboratories 的新股份，價值約 38,000 美元。目前，65.24% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>分析師升級和降級</h2>
<p>一些股票研究分析師最近對該股票發佈了報告。加拿大皇家銀行在 1 月 14 日的報告中重申了 “跑贏大盤” 的評級，並對 Bio-Rad Laboratories 的股票設定了 481.00 美元的目標價。富國銀行將 Bio-Rad Laboratories 的目標價從 360.00 美元下調至 345.00 美元，並在 2 月 12 日的報告中對該股票設定了 “持平” 的評級。最後，StockNews.com 在 2 月 17 日的報告中將 Bio-Rad Laboratories 的評級從 “買入” 下調至 “持有”。三位研究分析師對該股票給予了持有評級，三位分析師則給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為 395.20 美元。</p>
<ul>
<li>現在值得購買的前三大醫療設備股票</li>
</ul>
<p><strong>閲讀我們關於 BIO 的最新研究報告</strong></p>
<h2>Bio-Rad Laboratories 股票上漲 0.5%</h2>
<p>紐約證券交易所 BIO 的股票在週二開盤價為 244.29 美元。該公司的債務與股本比率為 0.18，速動比率為 4.85，流動比率為 6.48。Bio-Rad Laboratories, Inc.的 1 年最低價為 235.84 美元，1 年最高價為 387.99 美元。該股票的 50 日簡單移動平均線為 291.56 美元，200 日簡單移動平均線為 321.95 美元。該公司的市值為 68.4 億美元，市盈率為-3.76，貝塔值為 0.98。</p>
<p>Bio-Rad Laboratories（紐約證券交易所代碼：BIO - 獲取免費報告）最後一次公佈財報是在 2 月 13 日，醫療研究公司報告本季度每股收益（EPS）為 2.90 美元，超出分析師的共識預期 2.86 美元，超出幅度為 0.04 美元。Bio-Rad Laboratories 的股本回報率為 3.90%，淨利潤率為-71.86%。整體來看，股票分析師預計 Bio-Rad Laboratories, Inc.在當前財年將發佈 10.81 美元的每股收益。</p>
<h2>關於 Bio-Rad Laboratories</h2>
<p>（免費報告）</p>
<p>Bio-Rad Laboratories, Inc.在美國、歐洲、亞洲、加拿大和拉丁美洲製造和分銷生命科學研究和臨牀診斷產品。它通過兩個部門運營，分別是生命科學和臨牀診斷。該公司開發、製造和銷售儀器、系統、試劑和耗材，以分離、純化、表徵和定量生物材料，如細胞、蛋白質和核酸，服務於蛋白質組學、基因組學、生物製藥生產、細胞生物學和食品安全市場。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Bio-Rad Laboratories</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>3 只可購買的股票，底部堅實，準備反彈</li>
<li>10 月值得考慮購買的 3 只股票</li>
<li>Advantage+ 購物：Meta 快速增長的 200 億美元 AI 廣告明星</li>
<li>關於 Markup 計算器</li>
<li>Robotaxi 新聞：特斯拉和 Lyft 的頭條對股票的影響</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJJTw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Bio-Rad Laboratories 嗎？</h2>
<p>在你考慮 Bio-Rad Laboratories 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前...而 Bio-Rad Laboratories 並不在名單上。</p>
<p>雖然 Bio-Rad Laboratories 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Bio-Rad實驗室-A

<p>CIBC 私人財富集團有限公司在第四季度減少了對 Bio-Rad Laboratories, Inc.（紐約證券交易所代碼：BIO）2.9% 的持股，目前持有 42,106 股，價值 1450 萬美元。其他投資者，包括 Venturi Wealth Management 和 Picton Mahoney Asset Management，也調整了他們的持倉。分析師對該股票的評級不一，普遍評級為 “適度買入”，目標價為 395.20 美元。Bio-Rad 的股票開盤價為 244.29 美元，市值為 68.4 億美元，報告每股收益為 2.90 美元，超出預期</p>

<p>CIBC Private Wealth Group LLC lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 2.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,106 shares of the medical research company's stock after selling 1,243 shares during the quarter. CIBC Private Wealth Group LLC owned 0.15% of Bio-Rad Laboratories worth $14,500,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>CIBC 私人財富集團有限公司在最近向證券交易委員會的披露中表示，在第四季度將其在 Bio-Rad Laboratories, Inc.（紐約證券交易所代碼：BIO - 免費報告）的股份減少了 2.9%。該公司在本季度出售了 1,243 股後，持有 42,106 股該醫療研究公司的股票。根據其最近向證券交易委員會的備案，CIBC 私人財富集團有限公司持有 Bio-Rad Laboratories 的 0.15% 股份，價值 14,500,000 美元。</p>
</div><p>Get <strong>Bio-Rad Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Bio-Rad Laboratories</strong> 的提醒：</p>
</div><ul>
<li>S&amp;P 500 Shake-Up: New Entrants Driving Market Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>標普 500 震盪：新進入者推動市場動能</li>
</ul>
</div><p>Other large investors have also recently made changes to their positions in the company. Venturi Wealth Management LLC grew its position in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock valued at $30,000 after buying an additional 87 shares during the last quarter. Picton Mahoney Asset Management boosted its stake in shares of Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after acquiring an additional 35 shares in the last quarter. Asset Planning Inc acquired a new stake in Bio-Rad Laboratories in the 4th quarter valued at about $33,000. UMB Bank n.a. grew its holdings in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after buying an additional 32 shares during the last quarter. Finally, Cape Investment Advisory Inc. purchased a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth about $38,000. 65.24% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他大型投資者最近也對該公司的持倉進行了調整。Venturi 財富管理有限公司在第四季度將其在 Bio-Rad Laboratories 的股份增加了 2,175.0%。Venturi 財富管理有限公司現在擁有 91 股該醫療研究公司的股票，價值 30,000 美元，此前在上個季度又購買了 87 股。Picton Mahoney 資產管理在第四季度將其在 Bio-Rad Laboratories 的股份增加了 55.6%。Picton Mahoney 資產管理現在擁有 98 股該醫療研究公司的股票，價值 32,000 美元，此前在上個季度又收購了 35 股。Asset Planning Inc 在第四季度收購了 Bio-Rad Laboratories 的新股份，價值約 33,000 美元。UMB 銀行在第四季度將其在 Bio-Rad Laboratories 的持股增加了 41.6%。UMB 銀行現在擁有 109 股該醫療研究公司的股票，價值 36,000 美元，此前在上個季度又購買了 32 股。最後，Cape Investment Advisory Inc 在第四季度購買了 Bio-Rad Laboratories 的新股份，價值約 38,000 美元。目前，65.24% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>A number of equities research analysts recently issued reports on the stock. Royal Bank of Canada restated an &#34;outperform&#34; rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Wells Fargo &amp; Company dropped their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an &#34;equal weight&#34; rating on the stock in a report on Wednesday, February 12th. Finally, StockNews.com cut Bio-Rad Laboratories from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, February 17th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $395.20.</p>
<div class="lb-trans"><p>一些股票研究分析師最近對該股票發佈了報告。加拿大皇家銀行在 1 月 14 日的報告中重申了 “跑贏大盤” 的評級，並對 Bio-Rad Laboratories 的股票設定了 481.00 美元的目標價。富國銀行將 Bio-Rad Laboratories 的目標價從 360.00 美元下調至 345.00 美元，並在 2 月 12 日的報告中對該股票設定了 “持平” 的評級。最後，StockNews.com 在 2 月 17 日的報告中將 Bio-Rad Laboratories 的評級從 “買入” 下調至 “持有”。三位研究分析師對該股票給予了持有評級，三位分析師則給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價為 395.20 美元。</p>
</div><ul>
<li>The Top 3 Medical Devices Stocks to Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>現在值得購買的前三大醫療設備股票</li>
</ul>
</div><p><strong>Read Our Latest Research Report on BIO</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 BIO 的最新研究報告</strong></p>
</div><h2>Bio-Rad Laboratories Stock Up 0.5 %</h2>
<div class="lb-trans"><h2>Bio-Rad Laboratories 股票上漲 0.5%</h2>
</div><p>Shares of NYSE BIO opened at $244.29 on Tuesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. Bio-Rad Laboratories, Inc. has a 1 year low of $235.84 and a 1 year high of $387.99. The stock's 50-day simple moving average is $291.56 and its 200-day simple moving average is $321.95. The firm has a market cap of $6.84 billion, a price-to-earnings ratio of -3.76 and a beta of 0.98.</p>
<div class="lb-trans"><p>紐約證券交易所 BIO 的股票在週二開盤價為 244.29 美元。該公司的債務與股本比率為 0.18，速動比率為 4.85，流動比率為 6.48。Bio-Rad Laboratories, Inc.的 1 年最低價為 235.84 美元，1 年最高價為 387.99 美元。該股票的 50 日簡單移動平均線為 291.56 美元，200 日簡單移動平均線為 321.95 美元。該公司的市值為 68.4 億美元，市盈率為-3.76，貝塔值為 0.98。</p>
</div><p>Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Bio-Rad Laboratories（紐約證券交易所代碼：BIO - 獲取免費報告）最後一次公佈財報是在 2 月 13 日，醫療研究公司報告本季度每股收益（EPS）為 2.90 美元，超出分析師的共識預期 2.86 美元，超出幅度為 0.04 美元。Bio-Rad Laboratories 的股本回報率為 3.90%，淨利潤率為-71.86%。整體來看，股票分析師預計 Bio-Rad Laboratories, Inc.在當前財年將發佈 10.81 美元的每股收益。</p>
</div><h2>About Bio-Rad Laboratories</h2>
<div class="lb-trans"><h2>關於 Bio-Rad Laboratories</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.</p>
<div class="lb-trans"><p>Bio-Rad Laboratories, Inc.在美國、歐洲、亞洲、加拿大和拉丁美洲製造和分銷生命科學研究和臨牀診斷產品。它通過兩個部門運營，分別是生命科學和臨牀診斷。該公司開發、製造和銷售儀器、系統、試劑和耗材，以分離、純化、表徵和定量生物材料，如細胞、蛋白質和核酸，服務於蛋白質組學、基因組學、生物製藥生產、細胞生物學和食品安全市場。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Bio-Rad Laboratories</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>3 Buyable Stocks With Solid Bottoms Ready to Rebound</li>
<li>3 Stocks to Consider Buying in October</li>
<li>Advantage+ Shopping: Meta's Fast Growing $20 Billion AI-Ads Star</li>
<li>About the Markup Calculator</li>
<li>Robotaxi News: What Tesla and Lyft Headlines Mean for Shares</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Bio-Rad Laboratories</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>3 只可購買的股票，底部堅實，準備反彈</li>
<li>10 月值得考慮購買的 3 只股票</li>
<li>Advantage+ 購物：Meta 快速增長的 200 億美元 AI 廣告明星</li>
<li>關於 Markup 計算器</li>
<li>Robotaxi 新聞：特斯拉和 Lyft 的頭條對股票的影響</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJJTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bio-Rad Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Bio-Rad Laboratories 嗎？</h2>
</div><p>Before you consider Bio-Rad Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Bio-Rad Laboratories 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前...而 Bio-Rad Laboratories 並不在名單上。</p>
</div><p>While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Bio-Rad Laboratories 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

CIBC Private Wealth Group LLC 出售了 Bio-Rad Laboratories, Inc. (NYSE:BIO) 的股票